Related Experiment Video
Updated: Jun 25, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
Published on: March 1, 2024
Retrospective review of Pneumocystis jirovecii pneumonia over two decades
1Department of Infectious Diseases, The Monsall Unit, North Manchester General Hospital, Manchester, UK. jennytravis@doctors.org.uk
Abstract:
The aim of the study was to compare a retrospective case note review of all cases of Pneumocystis carinii (now Pneumocystis jirovecii) pneumonia (PJP) over the period 1997-2004 at North Manchester General Hospital with a previous audit covering the years 1986-1995. During 1986-1995, 777 patients were diagnosed with HIV. One hundred and eighty-one were also diagnosed with PJP. Of these, 11 patients required ventilation with a mortality rate of 100%. For the current review during 1997-2004, 210 patients were diagnosed with PJP, and 64 with severe PJP. Median age was 39 years (interquartile range [IQR] 22-61). Twenty-four patients had a prior diagnosis of HIV (median 43 months, IQR 6-72 months), and for 38 patients this was the presenting diagnosis of HIV. Median CD4 was 34 cells/L (IQR of 12-80 cells/L). Median viral load was 3.5 x 10(5) copies/mL (IQR 1-5.8 x 10(5) copies/mL). Eighteen patients required intubation during this period. Nine (50%) were alive at 30 days postextubation. We believe that the 50% reduction in mortality seen between 1997-2004 in intubated patients with severe PJP is due to the improvement in intensive care management of severe respiratory failure rather than changes in the specific management of PJP. The necessity of ventilation in HIV patients is no longer a mandatory death sentence.
Insights
Mortality for ventilated Pneumocystis pneumonia (PJP) patients with HIV significantly decreased by 50% between 1986-1995 and 1997-2004. This improvement is attributed to better intensive care, not specific PJP treatments.
Area of Science:
- Infectious Diseases
- Pulmonology
- Critical Care Medicine
Background:
- Pneumocystis pneumonia (PJP) is a severe opportunistic infection, particularly in individuals with Human Immunodeficiency Virus (HIV).
- Previous audits indicated a 100% mortality rate for ventilated PJP patients between 1986-1995.
Purpose of the Study:
- To compare PJP case notes from 1997-2004 with previous audit data (1986-1995).
- To assess changes in PJP patient demographics, management, and outcomes, particularly for severe cases requiring ventilation.
Main Methods:
- Retrospective case note review of PJP cases at North Manchester General Hospital (1997-2004).
- Comparison with an earlier audit of PJP cases (1986-1995).
- Analysis of patient demographics, HIV status, CD4 counts, viral load, and ventilation requirements.
Main Results:
- 210 PJP cases diagnosed 1997-2004, with 64 severe cases. Median age 39 years.
- 18 patients required intubation; 9 (50%) survived 30 days postextubation.
- Significant reduction in mortality for ventilated severe PJP patients compared to the 1986-1995 cohort (100% mortality).
Conclusions:
- Improved intensive care management of respiratory failure has led to a 50% reduction in mortality for ventilated severe PJP patients.
- Ventilation for HIV-positive patients with PJP is no longer a universally fatal outcome.
- Advances in critical care have significantly improved survival rates for severe PJP cases.
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: